Lupin Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe.

The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma's strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight.

VISUfarma enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement.

The product has been deemed bioequivalent to Merck & Co.?s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery.

Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement.

The product has been deemed bioequivalent to Merck & Co.?s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery.

Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The counter shed 0.95% to end at Rs 2,312.70 on the BSE.

Powered by Capital Market - Live News

Lupin announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi B.V., the Netherlands (Nanomi), which is a wholly owned subsidiary of the Company, has bought back 2,813,811 equity shares from some of its existing shareholders. Nanomi did not participate in the said buyback. This has resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.

Powered by Capital Market - Live News